Clinical Trials
15 trialsNCT01659151 2026-02-20
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT07410494 2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2 Recruiting
NCT05296564 2025-10-02
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
Phase 1/2 Recruiting
NCT05086692 2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03991741 2025-07-03
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
University of California, San Diego
Phase 1 Terminated
NCT03991130 2025-02-06
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
University of California, San Diego
Phase 2 Terminated
NCT01856023 2023-12-05
PROCLIVITY02
Clinigen, Inc.
Phase 4 Terminated
NCT01369875 2019-12-10
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02153905 2019-06-17
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01814046 2018-10-11
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01409174 2017-05-31
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01754376 2017-04-12
Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma
Massachusetts General Hospital
Phase 2 Terminated
NCT01273181 2015-10-28
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00001832 2012-12-21
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001705 2008-03-04
Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence
National Institutes of Health Clinical Center (CC)
Phase 2 Completed